These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3399005)

  • 61. Hyperdynamic therapy for cerebral vasospasm.
    Hadeishi H; Mizuno M; Suzuki A; Yasui N
    Neurol Med Chir (Tokyo); 1990 May; 30(5):317-23. PubMed ID: 1699147
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.
    Cheng Y; Liu M; Hu H; Liu D; Zhou S
    AAPS PharmSciTech; 2016 Apr; 17(2):409-17. PubMed ID: 26195071
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lipid microsphere-coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial.
    Wang J; Tang S; Xie Y; Liu J; Liu J; Wu H; Zhang H
    Semin Dial; 2021 May; 34(3):235-244. PubMed ID: 33592131
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of lipo-prostaglandin E1 on random pattern flaps in rabbits.
    Kuwahara H; Sugihara T; Ohura T; Igawa H; Yamamoto Y
    Scand J Plast Reconstr Surg Hand Surg; 1996 Mar; 30(1):23-8. PubMed ID: 8711438
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of prostaglandin E 1 on cerebral circulatory disturbances following subarachnoid haemorrage in man.
    Steiner L; Forster DM; Bergvall U; Carlson LA
    Neuroradiology; 1972 Jun; 4(1):20-4. PubMed ID: 5081231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Treatment of the peripheral vascular diseases with prostaglandin].
    Miyauchi Y
    Nihon Rinsho; 1994 Aug; 52(8):2182-6. PubMed ID: 7933609
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lipo-prostaglandin E1 improves renal hypoxia evaluated by BOLD-MRI in patients with diabetic kidney disease.
    Li ZC; Cai YZ; Tang ZG; Zuo PL; Liu RB; Liu F
    Clin Imaging; 2018; 50():239-242. PubMed ID: 29689479
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic effects of carbogen inhalation and lipo-prostaglandin E1 in sudden hearing loss.
    Lee HJ; Park CY; Lee JH; Yang HS; Kim JH; Ban MJ; Moon IS
    Yonsei Med J; 2012 Sep; 53(5):999-1004. PubMed ID: 22869484
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quantification of the effect of Lipo-PGE1 on angiogenesis.
    Eo S; Kwon C; Lee H; Cho S; Kim J; Baek G; Yeo J; Lim C
    J Plast Reconstr Aesthet Surg; 2015 Jan; 68(1):104-12. PubMed ID: 25448364
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.
    Tohyama M; Baba A; Tsuno T; Aonuma K; Komiyama A
    Eur J Pediatr; 1993 Nov; 152(11):877-9. PubMed ID: 8276014
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Skin sympathetic neuroeffector response is attenuated dose-dependently by systemic prostaglandin E1 injection in humans.
    Iwase S; Yamamoto K; Miwa C; Kamiya A; Niimi Y; Fu Q; Mano T
    Neurosci Lett; 2000 Oct; 292(3):191-4. PubMed ID: 11018309
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Review: recent advances in lipid microsphere technology for targeting prostaglandin delivery.
    Mizushima Y; Hoshi K
    J Drug Target; 1993; 1(2):93-100. PubMed ID: 8069557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prostaglandin E1 (PGE1): effect on the human fibrinolytic system.
    Narain VS; Saran RK; Dwivedi SK; Puri VK; Hasan M
    Indian Heart J; 1989; 41(5):326-9. PubMed ID: 2599544
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of fulminant hepatic failure with intravenous prostaglandin E1.
    Sterling RK; Luketic VA; Sanyal AJ; Shiffman ML
    Liver Transpl Surg; 1998 Sep; 4(5):424-31. PubMed ID: 9724481
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PGE1 improves diabetic peripheral neuropathy in patients with type 2 diabetes.
    Wu JD; Tao S; Jin X; Jiang LL; Shen Y; Luo Y; Zhang P; Lee KO; Ye L; Ma JH
    Prostaglandins Other Lipid Mediat; 2016 Nov; 126():24-28. PubMed ID: 27421690
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Actions of prostaglandin E1 on lipopolysaccharide-evoked responses in vivo and in vitro following resuscitated trauma.
    Stewart RM; Fabian TC; McGinty MP; Fabian MJ; Proctor KG
    Shock; 1995 Apr; 3(4):307-14. PubMed ID: 7600198
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of lipo prostaglandin E1 on distribution of cis-diamminedichloroplatinum in lung metastasis derived from Dunn osteosarcoma cell-inoculated mouse foot-pad.
    Watanabe T; Koshino T; Saito T; Takagi T; Machida J
    Cancer Lett; 1999 Jun; 140(1-2):153-60. PubMed ID: 10403554
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropathy.
    Tawata M; Nitta K; Kurihara A; Nagasaka T; Iwase E; Gan N; Inoue M; Onaya T
    Prostaglandins; 1995 Jan; 49(1):27-39. PubMed ID: 7792389
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lipo prostaglandin E1 reduces the production of CXC chemokines in endotoxin-induced rat liver injury.
    Ohira H; Suzuki T; Shishido S; Tojo J; Miyata M; Obara K; Kasukawa R
    Hepatol Res; 2001 Jan; 19(1):74-84. PubMed ID: 11137482
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors.
    Itoh Y; Yasui T; Kakizawa H; Makino M; Fujiwara K; Kato T; Imamura S; Yamamoto K; Hishida H; Nakai A; Itoh M; Nagasaka A
    Prostaglandins Other Lipid Mediat; 2001 Oct; 66(3):221-34. PubMed ID: 11577785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.